Effects of High-flow Oxygen Therapy and Non-invasive Ventilation on Lung Volumes and on Upper Airway
- Conditions
- Respiratory Failure
- Registration Number
- NCT05643911
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Respiratory failure is the most frequent organ failure and cause for admission in the Intensive Care Unit (ICU) . It is a severe complication with an ICU mortality ranged from 31% to 33%. Symptomatic treatment of hypoxemic respiratory failure is a controversial topic with different options: 1) standard oxygen therapy, 2) high flow nasal cannula oxygen therapy (HFNC) and 3) non-invasive ventilation (NIV).
The aim of the study is to compare HFNC versus NIV ventilation using CT scan. The hypothesis of this study is that in hypoxemic critically ill patients, the increase of lung volumes with NIV would be significantly higher than the increase of lung volumes with HFNC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 56
- Patient with hypoxemia at any time of ICU stay defined as follow: standard oxygen therapy flow ≥ 3L/min to maintain a pulsed oxygen saturation ≥ 95%
- Adult (age ≥ 18 years)
- (2) A CT scan prescribed by the physician in charge of the patient as part of the exploration of the patient's pathology and not as part of a "dedicated" prescription for the study.
- NIV contraindication (need for immediate endotracheal intubation and mechanical ventilation; hemodynamic instability defined by systolic blood pressure < 90 mmHg or mean blood pressure < 65 mmHg, use of vasopressors; Glasgow Coma Scale score of 12 points or less)
- History of recent facial trauma not compatible with the use of nasal cannulas
- Pregnancy
- Refusal of study participation
- protected person
- Patient not affiliated to the social security system or not benefiting from such a system
- Lack of signed informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Variation in poorly aerated lung volume the day of inclusion The poorly aerated volume will be measured by CT scan
Variation in non-aereted lung volume the day of inclusion The non-aereted volume will be measured by CT scan
- Secondary Outcome Measures
Name Time Method Variation in cross-sectional upper airway area the day of inclusion The variation will be measured by CT-scan in mm
Variation in Positive End Expiratory Pressure (PEEP) the day of inclusion Variation in Total lung volume the day of inclusion The total lung volume will be measured by CT-scan
Variation in normally aerated lung volume the day of inclusion The normally aerated lung volume will be measured by CT scan
Variation in respiratory rate the day of inclusion Respiratory rate is the number of cycles per minute
Variation in cardiac output (Qc) the day of inclusion the cardiac output is in L/min
Variation in O2 gas exchange the day of inclusion Change in PaO2 in mmHg
Variation in CO2 gas exchange the day of inclusion Change in PaO2 in mmHg
Variation in patient comfort the day of inclusion Patient comfort through a numeric rating scale (NRS) from 0 (no discomfort) to 10 (maximum imaginable discomfort)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire Montpellier, Saint Eloi
🇫🇷Montpellier, Languedoc-Roussillon, France
Centre Hospitalier Universitaire Montpellier, Saint Eloi🇫🇷Montpellier, Languedoc-Roussillon, FranceSamir JABER, MD, PhDPrincipal InvestigatorAudrey De JONG, MDSub InvestigatorClément MONET, MDSub InvestigatorMatthieu CONSEIL, MDSub Investigator